Macular neovascularization within 1 year of avacincaptad pegol therapy worsens outcomes compared with patients without ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

An event aimed at raising awareness of the most common cause of sight loss in the UK will return to Doncaster next month.

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.